Prusogliptin Tablets | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Company: CSPC Ouyi Pharmaceutical Co., Ltd.
Medicine type: Chemical medicine
Therapeutic area: Endocrinology & metabolism
Indications recorded in the public source: To improve glycemic control in adults with type 2 diabetes: (1) as monotherapy alongside diet and exercise; (2) in combination with metformin hydrochloride alongside diet and exercise when metformin hydrochloride alone does not provide adequate glycemic control. Important limitations of use: not indicated for type 1 diabetes or diabetic ketoacidosis.
Indication source and scope: Source date(s): 2025. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label. Additional indications may be supported by newer announcements or submissions rather than the older full label; see the indication sources.
Prescribing-information limitations: Indications checked against an official public submission. The full original prescribing information is still unavailable.
China availability status: Historical Chinese approval verified; current continuous market availability has not been checked for every product.
Overseas status: Market-by-market verification pending.
Insurance classification: Not matched in the 2025 national list; manual review pending
Insurance edition: 2025 edition; effective 1 January 2026
Insurance verification notes: No match in the extracted directory is not proof of exclusion. Compound formulations still require manual review.

Sources

Open the interactive record, public price references and discussions